Glenmark Pharma Quarterly Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Glenmark Pharma Quarterly Results    (GLPH)

Here are the latest quarterly results of Glenmark Pharma. For more details, see the Glenmark Pharma financial fact sheet and Glenmark Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

Excel Export | Annual Financial Info | Result Scoreboard

Glenmark Pharma Quarterly Results

No. of Mths
Qtr. Ending
3
Mar-18
*
3
Jun-18
*
3
Sep-18
*
3
Dec-18
*
3
Mar-19
*
3
Jun-19
*
3
Sep-19
*
3
Dec-19
*
8-Qtr Chart
Click to enlarge
Net Sales Rs m22,79821,65625,81325,55025,63523,22928,15027,356 
Other income Rs m6961,3821,399-1,09039117808330 
Turnover Rs m23,49423,03827,21224,46026,02523,24528,95927,685 
Expenses Rs m19,53018,18721,41221,20421,99319,81023,64622,955 
Gross profit Rs m3,2683,4696,0734,3473,6413,4194,5044,401 
Depreciation Rs m7357948258318109079421,060 
Interest Rs m744790851885819930898961 
Profit before tax Rs m2,4853,2675,7961,5402,4031,5983,4732,710 
Tax Rs m9689371,656377786506918801 
Profit after tax Rs m1,5162,3304,1401,1631,6171,0932,5551,908 
Gross profit margin %14.316.023.517.014.214.716.016.1 
Effective tax rate %39.028.728.624.532.731.626.429.6 
Net profit margin %6.710.816.04.66.34.79.17.0 
Diluted EPS Rs 5.4 8.3 14.7 4.1 5.7 3.9 9.1 6.8  
Diluted EPS (TTM) Rs 28.5 24.9 32.0 32.4 32.8 28.4 22.8 25.4  
 Subscriber Feature                  
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Read: Glenmark Pharma 3QFY20 Result Performance Review

More Pharmaceuticals Company Quarterly Results:   UNICHEM LAB  SUN PHARMA  NATCO PHARMA  AJANTA PHARMA  STRIDES PHARMA SCIENCE  

Compare GLENMARK PHARMA With:   UNICHEM LAB  SUN PHARMA  NATCO PHARMA  AJANTA PHARMA  STRIDES PHARMA SCIENCE  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Surges 1,266 Points; Nifty Ends Above 9,100 Mark(Closing)

Indian share markets witnessed buying interest throughout the day and ended on a strong note.

Views on news

LUPIN Surges by 13%; BSE HEALTHCARE Index Up 3.4% (Market Updates)

Apr 9, 2020 | Updated on Apr 9, 2020

LUPIN share price has surged by 13% and its current market price is Rs 798. The BSE HEALTHCARE is up by 3.4%. The top gainers in the BSE HEALTHCARE Index are LUPIN (up 12.7%) and DIVIS LABORATORIES (up 6.2%). The top losers are J.B.CHEMICALS (down 0.2%) and PROCTER & GAMBLE HEALTH (down 1.2%).

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020 (The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

One Stock that is All Charged Up for the Post Coronavirus Rebound (The 5 Minute Wrapup)

Apr 1, 2020

A stock with strong moat is currently trading near 5-year lows.

A Safe Stock to Lockdown Now (The 5 Minute Wrapup)

Apr 2, 2020

The market crashc has made strong, established brands attractive. Here's a stock to make the most of this opportunity...

The Insiders See a Buying Opportunity in These Smallcaps Amid Coronavirus Outbreak (Profit Hunter)

Mar 31, 2020

The promoters are buying these smallcaps amid the coronavirus outbreak.

How to Identify a Market Rebound (Fast Profits Daily)

Mar 27, 2020

This very useful indicator can spot a market bottom.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Apr 9, 2020 03:37 PM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - IPCA LABS COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS